Oxidized recombinant human growth hormone that maintains conformational integrity

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 110-122

  Mulinacci, Filippo ^a   Bell, Steven E J ^b   Capelle, Martinus A H ^a   Gurny, Robert ^a   Arvinte, Tudor ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Circular dichroism; Conformation; Fluorescence spectroscopy; Human growth hormone; Light scattering; Oxidation; Raman spectroscopy; Ultrasonic resonance technology

Indexed keywords

HUMAN GROWTH HORMONE; HYDROGEN PEROXIDE; METHIONINE;

ARTICLE; CHROMATOGRAPHY; CIRCULAR DICHROISM; FLUORESCENCE SPECTROSCOPY; LIGHT SCATTERING; MASS SPECTROMETRY; OXIDATION; PEPTIDE MAPPING; PROTEIN CONFORMATION; RAMAN SPECTROMETRY; ULTRASOUND; ULTRAVIOLET RADIATION;

EID: 78650069557     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22268     Document Type: Article

References (54)

1. Lura R, Schirch V. 1988. Role of peptide conformation in the rate and mechanism of deamidation of asparaginyl residues. Biochemistry 27: 7671-7677.
2. Antipas AS, Velde DCV, Jois SDS, Siahaan T, Stella VJ. 2000. Effect of conformation on the rate of deamidation of vancomycin in aqueous solutions. J Pharm Sci 89: 742-750.
3. Wearne SJ, Creighton TE. 1989. Effect of protein conformation on rate of deamidation-Ribonuclease-A. Proteins 5: 8-12.
4. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511.
5. Stefani M, Dobson CM. 2003. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678-699.
6. Shechter Y, Burstein Y, Patchornik A. 1975. Selective oxidation of methionine residues in proteins. Biochemistry 14: 4497-4503.
7. Liu JL, Lu KV, Eris T, Katta V, Westcott KR, Narhi LO, Lu HS. 1998. In vitro methionine oxidation of recombinant human leptin. Pharm Res 15: 632-640.
8. Vogt W. 1995. Oxidation of methionyl residues in proteins-Tools, targets, and reversal. Free Radic Biol Med 18: 93-105.
9. Devos AM, Ultsch M, Kossiakoff AA. 1992. Human growth-hormone and extracellular domain of its receptor-Crystal-structure of the complex. Science 255: 306-312.
10. Li CH, Dixon JS. 1971. Human pituitary growth hormone: XXXII. The primary structure of the hormone: Revision. Arch Biochem Biophys 146: 233-236.
11. Strobl JS, Thomas MJ. 1994. Human growth-hormone. Pharmacol Rev 46: 1-34.
12. Ueland T. 2004. Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res 14: 404-417.
13. Olney RC. 2003. Regulation of bone mass by growth hormone. Med Pediatr Oncol 41: 228-234.
14. Eiholzer U, Gisin R, Weinmann C, Kriemler S, Steinert H, Torresani T, Zachmann M, Prader A. 1998. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 157: 368-377.
15. Leger J, Garel C, Fjellestad-Paulsen A, Hassan M, Czernichow P. 1998. Human growth hormone treatment of short-stature children born small for gestational age: Effect on muscle and adipose tissue mass during a 3-year treatment period and after 1 year's withdrawal. J Clin Endocrinol Metab 83: 3512-3516.
16. Lucidi P, Laureti S, Santoni S, Lauteri M, Busciantella-Ricci N, Angeletti G, Santeusanio F, De Feo P. 2000. Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults. Clin Endocrinol 52: 173-179.
17. Teshima G, Canovadavis E. 1992. Separation of oxidized human growth-hormone variants by reversed-phase high-performance liquid-chromatography-Effect of mobile phase Ph and organic modifier. J Chromatogr 625: 207-215.
18. Lakowicz JR, Maliwal BP, Cherek H, Balter A. 1983. Rotational freedom of tryptophan residues in proteins and peptides. Biochemistry 22: 1741-1752.
19. Lakowicz JR. 2006. Principles of fluorescence spectroscopy, 3rd edition. Berlin, Germany: Springer.
20. Karlsson G, Gellerfors P, Persson A, Noren B, Edlund PO, Sandberg C, Birnbaum S. 1999. Separation of oxidized and deamidated human growth hormone variants by isocratic reversed-phase high-performance liquid chromatography. J Chromatogr A 855: 147-155.
21. Riggin RM, Dorulla GK, Miner DJ. 1987. A reversed-phase high-performance liquid-chromatographic method for characterization of biosynthetic human growth-hormone. Anal Biochem 167: 199-209.
22. Battersby JE, Hancock WS, Canovadavis E, Oeswein J, Oconnor B. 1994. Diketopiperazine formation and N-terminal degradation in recombinant human growth-hormone. Int J Pept Protein Res 44: 215-222.
23. Chantalat L, Jones ND, Korber F, Navaza J, Pavlovsky AG. 1995. The crystal-structure of wild-type growth-hormone at 2.5 angstrom resolution. Protein Pept Lett 2: 333-340.
24. Clackson T, Ultsch MH, Wells JA, De Vos AM. 1998. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol 277: 1111-1128.
25. Sundstrom M, Lundqvist T, Rodin J, Giebel LB, Milligan D, Norstedt G. 1996. Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 angstrom resolution. J Biol Chem 271: 32197-32203.
26. Teh LC, Murphy LJ, Huq NL, Surus AS, Friesen HG, Lazarus L, Chapman GE. 1987. Methionine oxidation in human growth-hormone and human chorionic somatomammotropin-Effects on receptor-binding and biological-activities. J Biol Chem 262: 6472-6477.
27. Cantor CR, Schimmel PR. 1980. Biophysical chemistry: Part II-Techniques for the study of biological structure and function, 1st edition. CA, USA: W.H. Freeman.
28. Wen ZQ. 2007. Raman spectroscopy of protein pharmaceuticals. J Pharm Sci 96: 2861-2878.
29. US Food and Drug Administration. 2003. Impurities in new drug products-ICH Q3B(R2). FDA Fed Regist 68: 64628-64629.
30. Caldwell P, Luk DC, Weissbach H, Brot N. 1978. Oxidation of methionine residues of Escherichia-coli ribosomal-protein L12 decreases proteins biological-activity. Proc Natl Acad Sci USA 75: 5349-5352.
31. Ananthas TS, Atreyi M, Maeda H, Meienhof J. 1974. Selective tryptophan oxidation in antitumor protein neocarzinostatin and effects on conformation and biological-activity. Biochemistry 13: 1007-1014.
32. Gao J, Yin DH, Yao YH, Sun HY, Qin ZH, Schoneich C, Williams TD, Squier TC. 1998. Loss of conformational stability in calmodulin upon methionine oxidation. Biophys J 74: 1115-1134.
33. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL. 2008. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47: 5088-5100.
34. DuTeaux SB, Berger T, Hess RA, Sartini BL, Miller MG. 2004. Male reproductive toxicity of trichloroethylene: Sperm protein oxidation and decreased fertilizing ability. Biol Reprod 70: 1518-1526.
35. Morgan PE, Sturgess AD, Davies MJ. 2005. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52: 2069-2079.
36. Yazici C, Kose K, Calis M, Demir M, Kirnap M, Ates F. 2004. Increased advanced oxidation protein products in Behcet's disease: A new activity marker? Br J Dermatol 151: 105-111.
37. Maleknia SD, Reixach N, Buxbaum JN. 2006. Oxidation inhibits amyloid fibril formation of transthyretin. FEBS J 273: 5400-5406.
38. Jayaraman S, Gantz DL, Gursky O. 2008. Effects of protein oxidation on the structure and stability of model discoidal high-density lipoproteins. Biochemistry 47: 3875-3882.
39. Jayaraman S, Gantz DL, Gursky O. 2007. Effects of oxidation on the structure and stability of human low-density lipoprotein. Biochemistry 46: 5790-5797.
40. Gaza-Bulseco G, Faidu S, Hurkmans K, Chumsae C, Liu HC. 2008. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J Chromatogr B 870: 55-62.
41. Becker GW, Riggin RM. 1991. Novel derivative of Human Growth Hormone (US Patent 5068317), Vol. 168, 208th edition. Indianapolis (USA): Eli Lilly and Company.
42. Allen FH, Bird CM, Rowland RS, Raithby PR. 1997. Hydrogen-bond acceptor and donor properties of divalent sulfur (Y-S-Z and R-S-H). Acta Crystallogr B 53: 696-701.
43. Nelson DL, Cox MM. 2004. Lehninger principles of biochemistry, 4th edition. USA: W.H. Freeman.
44. Bandyopadhyay S, Chakraborty S, Balasubramanian S, Bagchi B. 2005. Sensitivity of polar solvation dynamics to the secondary structures of aqueous proteins and the role of surface exposure of the probe. J Am Chem Soc 127: 4071-4075.
45. Cser A, Nagy K, Biczok L. 2002. Fluorescence lifetime of Nile Red as a probe for the hydrogen bonding strength with its microenvironment. Chem Phys Lett 360: II.
46. Zhuang XW, Ha T, Kim HD, Centner T, Labeit S, Chu S. 2000. Fluorescence quenching: A tool for single-molecule protein-folding study. Proc Natl Acad Sci USA 97: 14241-14244.
47. Demeule B, Gurny R, Arvinte T. 2007. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm 329: 37-45.
48. Ciruela F. 2008. Fluorescence-based methods in the study of protein-protein interactions in living cells. Curr Opin Biotechnol 19: 338-343.
49. Yan YL, Marriott G. 2003. Analysis of protein interactions using fluorescence technologies. Curr Opin Chem Biol 7: 635-640.
50. Kakehi K, Oda Y, Kinoshita M. 2001. Fluorescence polarization: Analysis of carbohydrate-protein interaction. Anal Biochem 297: 111-116.
51. Sackett DL, Wolff J. 1987. Nile Red as a polarity-sensitive fluorescent-probe of hydrophobic protein surfaces. Anal Biochem 167: 228-234.
52. Matulis D, Lovrien R. 1998. 1-anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. Biophys J 74: 422-429.
53. Houghten RA, Glaser CB, Li CH. 1977. Human somatotropin: Reaction with hydrogen peroxide. Arch Biochem Biophys 178: 350-355.
54. Wen ZQ, Thomas GJ. 1998. UV resonance Raman spectroscopy of DNA and protein constituents of viruses: Assignments and cross sections for excitations at 257, 244, 238, and 229nm. Biopolymers 45: 247-256.